Spine Top Stories Intrinsic Therapeutics Announces Initial Release of Its Next Generation Barricaid Narrow Anchor Device Designed to Reduce Reherniation After Back Surgery byTim AllenMarch 4, 2026
Spine Intrinsic Therapeutics Announces the First Endoscopic Barricaid Implantation in the Great Lakes Region by Dr. Nick Nenadovich byJosh SandbergNovember 14, 2025
Regulatory Spine Intrinsic Therapeutics Announces that AMA Released CPT 2026 Code Set Including New CPT Code 63032 Describing Bone-Anchored Annular Closure, Effective January 1, 2026 byJosh SandbergOctober 24, 2025
Spine Top Stories Intrinsic Therapeutics Announces the First Implantation of the Barricaid® Annular Closure Device Under Awake Sedation byJosh SandbergSeptember 2, 2025
Spine Top Stories Intrinsic Therapeutics Appoints Industry Veterans Mike Lytle and Dave Decker to Lead Sales and Advance Discectomy Treatment byTim AllenAugust 19, 2025
Spine Intrinsic Therapeutics Announces New Category 1 CPT Code for Bone Anchored Annular Closure, including the Barricaid® Annular Closure Device, to Treat Patients Undergoing Lumbar Discectomy for Herniated Discs byTim AllenOctober 24, 2024
Regulatory Spine Surgeons Taking New Steps to Build on Barricaid Facility Coding Success, Specialty Society Guidelines byJosh SandbergJune 1, 2020
Spine NYU Langone Performs First U.S. Procedure with Newly Approved Device to Reduce Herniated Disc Recurrence byJosh SandbergJune 12, 2019
Financial Intrinsic Therapeutics Completes $52m Financing to Fuel Commercial Efforts in the United States to Benefit Lumbar Discectomy Patients byJosh SandbergApril 12, 2019
Spine Top Stories Pivotal Clinical Trial Demonstrates Superiority of Anular Closure Compared to Standard Lumbar Discectomy byJosh SandbergJune 4, 2018
